Key result
Factor IIa inhibitor twice daily plus a P2Y12 inhibitor reduced TIMI major or minor bleeding compared to triple antithrombotic therapy.
Why the study?
The optimal antithrombotic strategy, especially regarding oral anticoagulants, for atrial fibrillation patients with bleeding and thrombosis risk after percutaneous coronary intervention remains unknown.
Does dual antithrombotic therapy with different oral anticoagulants improve safety and efficacy outcomes compared to triple therapy in patients with atrial fibrillation after percutaneous coronary intervention?
Meta-Analysis (n=11,532)
Open-label
Does dual antithrombotic therapy with different oral anticoagulants improve safety and efficacy outcomes compared to triple therapy in patients with atrial fibrillation after percutaneous coronary intervention?
In patients with AF after PCI, dual therapy with a factor IIa inhibitor 110 mg bid or factor Xa inhibitor plus a P2Y12 inhibitor optimizes bleeding safety, while factor IIa inhibitor 150 mg bid or VKA dual therapy may be preferred for specific ischemic risks.
Answers are grounded in this paper and cite their sources.
Factor IIa inhibitor 110 mg bid plus P2Y12 inhibitor may be preferred to minimize bleeding in AF post-PCI; extends trial data via meta-analysis on dual antithrombotic strategies.
The optimal antithrombotic strategy, especially regarding oral anticoagulants (OACs) for atrial fibrillation (AF) patients with bleeding and thrombosis risk after percutaneous coronary intervention (PCI), remains unknown. This study explored the optimal oral anticoagulants for AF patients after PCI using a meta-analysis. Randomised controlled trials were identified from PubMed, Embase, and the Cochrane Library through December 2020. Risk ratios, 95% confidence intervals, and random-effects models were used to compare different antithrombotic strategies through network meta-analysis, and the combination of antithrombotic agents was ranked according to the surface under the cumulative ranking curve and rankograms. Interval plots were drawn to observe pairwise comparisons between the different strategies. Five studies of 11,532 patients were included. Factor IIa inhibitor 110 mg bid plus a P2Y12 inhibitor had the greatest advantage for reducing Thrombolysis In Myocardial Infarction (TIMI) major or minor bleeding; Factor Xa inhibitor plus a P2Y12 inhibitor had the greatest advantage for reducing International Society on Thrombosis and Hemostasis major bleeding. For patients at risk of stroke plus all-cause death, factor IIa inhibitor 150 mg bid plus a P2Y12 inhibitor should be prioritised, and for those at risk of myocardial infarction and stent thrombosis, vitamin K antagonists plus a P2Y12 inhibitor were preferred. Factor IIa inhibitor 110 mg, factor IIa inhibitor 150 mg, factor Xa inhibitor and vitamin K antagonists should be selected in different situations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a meta-analysis in Atrial fibrillation after percutaneous coronary intervention (n=11,532). Factor IIa inhibitor plus P2Y12 inhibitor vs. Triple antithrombotic therapy (VKA + P2Y12 inhibitor + aspirin) was evaluated on TIMI major or minor bleeding (RR 0.42, 95% CI 0.25-0.72). Factor IIa inhibitor twice daily plus a P2Y12 inhibitor reduced TIMI major or minor bleeding compared to triple antithrombotic therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: